Soliris sends Alexion soaring

With the launch of a new product, second quarter revenues skyrocketed for Cheshire-based Alexion Pharmaceuticals Inc. The company’s quarterly revenue reached $9.8 million from $0.3 million at the same time last year, following the first commercial sales in the U.S. and Europe of Soliris, a drug used to treat a rare blood disorder. Gross profits reached $8.7 million, accounting for more than $1 million in product sales costs for the quarter.